Gemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia and non-alcoholic steatohepatitis (NASH). It is developing gemcabene, a novel, once-daily, oral therapy, for high risk cardiovascular patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies, primarily statin therapy, and for those patients who present with NASH. The company was founded in 2008 and is headquartered in Livonia, Michigan.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone734-245-1700
Debt
Current Ratio3.27
Quick Ratio3.27
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Price / Cash FlowN/A
Price / Book2.84
Profitability
Net Income$-33,410,000.00
Net MarginsN/A
Return on Assets-99.44%
Miscellaneous
Employees18
OptionableOptionable
Gemphire Therapeutics (NASDAQ:GEMP) Frequently Asked Questions
What is Gemphire Therapeutics' stock symbol?
Gemphire Therapeutics trades on the NASDAQ under the ticker symbol "GEMP."
How were Gemphire Therapeutics' earnings last quarter?
Gemphire Therapeutics Inc (NASDAQ:GEMP) posted its quarterly earnings results on Thursday, November, 8th. The company reported ($0.43) EPS for the quarter, beating the consensus estimate of ($0.47) by $0.04. View Gemphire Therapeutics' Earnings History.
When is Gemphire Therapeutics' next earnings date?
What price target have analysts set for GEMP?
5 analysts have issued 1-year price targets for Gemphire Therapeutics' stock. Their forecasts range from $6.00 to $30.00. On average, they expect Gemphire Therapeutics' share price to reach $20.20 in the next year. This suggests a possible upside of 1,823.8% from the stock's current price. View Analyst Price Targets for Gemphire Therapeutics.
What is the consensus analysts' recommendation for Gemphire Therapeutics?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gemphire Therapeutics in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Gemphire Therapeutics.
What are Wall Street analysts saying about Gemphire Therapeutics stock?
Here are some recent quotes from research analysts about Gemphire Therapeutics stock:
- 1. According to Zacks Investment Research, "Gemphire Therapeutics Inc. is a biopharmaceutical company. It focused on developing and commercializing therapies for the treatment of dyslipidemia. The company's product candidate is gemcabene (CI-1027), an oral therapy for patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies. Gemphire Therapeutics Inc. is headquartered in Northville, Michigan. " (1/4/2019)
- 2. Canaccord Genuity analysts commented, "We expect the study to continue under higher safety scrutiniy, and will carefully watch for any changes." (8/13/2018)
Has Gemphire Therapeutics been receiving favorable news coverage?
Media stories about GEMP stock have trended positive recently, according to InfoTrie. The research firm rates the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Gemphire Therapeutics earned a media sentiment score of 2.3 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 5.0 out of 10, indicating that recent media coverage is somewhat likely to have an impact on the company's share price in the near term.
Who are some of Gemphire Therapeutics' key competitors?
Some companies that are related to Gemphire Therapeutics include Synergy Pharmaceuticals (SGYP), Forward Pharma A/S (FWP), Evoke Pharma (EVOK), IntelGenx Technologies (IGXT), Nemus Bioscience (NMUS), Adial Pharmaceuticals (ADIL), ContraFect (CFRX), VIVUS (VVUS), Vaccinex (VCNX), Trevena (TRVN), DiaMedica Therapeutics (DMCAF), OncoSec Medical (ONCS), Aravive (ARAV), DiaMedica Therapeutics (DMAC) and Vascular Biogenics (VBLT).
Who are Gemphire Therapeutics' key executives?
Gemphire Therapeutics' management team includes the folowing people:
- Dr. Charles L. Bisgaier, Co-Founder, Chairman & Chief Scientific Officer (Age 64)
- Dr. Steven R. Gullans, CEO, Pres, Director, Principal Financial Officer & Principal Accounting Officer (Age 65)
- Mr. Seth Reno, Chief Commercial Officer (Age 51)
- Ms. Amy Zaremba Rabourn, Director of Fin.
- Dr. Carmen Daniela Oniciu Ph.D., VP of Preclinical R&D and Manufacturing (Age 61)
When did Gemphire Therapeutics IPO?
(GEMP) raised $30 million in an initial public offering (IPO) on Friday, August 5th 2016. The company issued 3,000,000 shares at a price of $10.00 per share. Jefferies and RBC Capital Markets served as the underwriters for the IPO and Canaccord Genuity and Roth Capital Partners were co-managers.
Who are Gemphire Therapeutics' major shareholders?
Gemphire Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Virtu Financial LLC (0.24%). Company insiders that own Gemphire Therapeutics stock include Andy Sassine and Steven R PhD Gullans. View Institutional Ownership Trends for Gemphire Therapeutics.
Which major investors are buying Gemphire Therapeutics stock?
GEMP stock was purchased by a variety of institutional investors in the last quarter, including Virtu Financial LLC. Company insiders that have bought Gemphire Therapeutics stock in the last two years include Andy Sassine and Steven R PhD Gullans. View Insider Buying and Selling for Gemphire Therapeutics.
How do I buy shares of Gemphire Therapeutics?
Shares of GEMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Gemphire Therapeutics' stock price today?
One share of GEMP stock can currently be purchased for approximately $1.05.
How big of a company is Gemphire Therapeutics?
Gemphire Therapeutics has a market capitalization of $12.84 million. The company earns $-33,410,000.00 in net income (profit) each year or ($3.23) on an earnings per share basis. Gemphire Therapeutics employs 18 workers across the globe.
What is Gemphire Therapeutics' official website?
How can I contact Gemphire Therapeutics?
Gemphire Therapeutics' mailing address is 17199 N. LAUREL PARK DRIVE SUITE 401, LIVONIA MI, 48152. The company can be reached via phone at 734-245-1700 or via email at [email protected]
MarketBeat Community Rating for Gemphire Therapeutics (NASDAQ GEMP)
MarketBeat's community ratings are surveys of what our community members think about Gemphire Therapeutics and other stocks. Vote "Outperform" if you believe GEMP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GEMP will underperform the S&P 500 over the long term. You may vote once every thirty days.
